Liminatus Pharma
LIMN
12 hedge funds and large institutions have $193K invested in Liminatus Pharma in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 → 12 (+2)
0.17% more ownership
Funds ownership: 1.01% → 1.17% (+0.17%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
56% less capital invested
Capital invested by funds: $437K → $193K (-$244K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$78.8K |
| 2 |
Two Sigma Investments
New York
|
+$39.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$13.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.83K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$66.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$23.5K |
| 3 |
Squarepoint
New York
|
-$17.4K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$27 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $44.8K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $43.3K | +$78.8K | +70,930 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $39.7K | +$1.46K | +1,317 | +2% |
|
|
4
Two Sigma Investments
New York
| $21.5K | +$39.2K | +35,284 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $11.8K | -$23.5K | -21,131 | -52% |
|
6
State Street
Boston,
Massachusetts
| $11.6K | – | – | – |
|
7
BlackRock
New York
| $8.09K | – | – | – |
|
|
TSS
8
Two Sigma Securities
New York
| $7.24K | +$13.2K | +11,875 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $5.43K | +$7.83K | +7,055 | +382% |
|
|
10
Bank of America
Charlotte,
North Carolina
| $27 | -$27 | -24 | -35% |
|
|
FFA
11
Farther Finance Advisors
San Francisco,
California
| $19 | – | – | – |
|
12
Citigroup
New York
| $1 | +$1 | +1 | New |
|
|
13
Jane Street
New York
| – | -$66.2K | -39,635 | Closed |
|
|
14
Squarepoint
New York
| – | -$17.4K | -10,403 | Closed |
|
LIMN Hedge Fund Activity: Q4 2025 in Review
12 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma (LIMN) for Q4 2025, worth a combined $193K — down 56% from $437K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LIMN positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $78.8K. The largest seller was Jane Street, exiting entirely with an estimated $66.2K sold.
- 12 institutional investors held Liminatus Pharma (LIMN) as of Q4 2025, up from 10 in Q3 2025.
- Funds reported $193K of Liminatus Pharma stock for Q4 2025, down 56% quarter-over-quarter.
- 4 funds opened new Liminatus Pharma positions in Q4 2025 and 2 closed out, a net change of +2 holders.
- The largest Liminatus Pharma buyer in Q4 2025 was Citadel Advisors, an estimated $78.8K added.
- The largest Liminatus Pharma seller in Q4 2025 was Jane Street, an estimated $66.2K sold.
Based on aggregated 13F filings for Q4 2025.